Company profile: vTv Therapeutics
1.1 - Company Overview
Company description
- Provider of small-molecule therapeutics addressing unmet medical needs, including: TTP399, a liver-selective glucokinase activator adjunct to insulin for type 1 diabetes to reduce hypoglycemia; HPP737, a PDE4 inhibitor for psoriasis with potential in COPD and atopic dermatitis; TTP273, an oral GLP-1 receptor agonist for type 2 diabetes; and a Nrf2/Bach1 program to reduce oxidative stress and inflammation.
Products and services
- HPP737: A potent, selective PDE4 inhibitor in development for psoriasis, architected to block PDE4 activity with potential applications in COPD and atopic dermatitis
- TTP273: An oral, small-molecule GLP-1 receptor agonist evaluated for type 2 diabetes mellitus, demonstrating significant HbA1c reductions and trends toward weight loss
- TTP399: An oral, small-molecule, liver-selective glucokinase activator developed as adjunct therapy to insulin in type 1 diabetes, aimed at reducing hypoglycemic episodes
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to vTv Therapeutics
Principia Biopharma
HQ: United States
Website
- Description: Provider of pre-clinical discovery and development of differentiated oral small-molecule therapies for inflammatory and autoimmune diseases and cancer, addressing significant unmet medical needs in immunology and oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Principia Biopharma company profile →
Graviton
HQ: United States
Website
- Description: Provider of clinical-stage biotech therapies, developing selective ROCK2 inhibitors for fibrotic, autoimmune and CNS diseases; a C6 monoclonal antibody for neurodegenerative diseases; and DYRK inhibitors for diabetes, neurological disorders and cancers. Conducts clinical trials and partners with Ovid Therapeutics and Sino Biopharmaceutical for development and commercialization.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Graviton company profile →
Greer Laboratories
HQ: United States
Website
- Description: Provider of subcutaneous immunotherapy and allergenic extracts for allergy diagnosis and treatment, including non-standardized extracts; short ragweed pollen and short/giant ragweed pollen mix extracts; standardized cat hair extracts for asthma, rhinitis, and conjunctivitis; and standardized grass pollen extracts for skin test diagnosis and immunotherapy to reduce allergic symptoms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Greer Laboratories company profile →
Eleusis
HQ: United Kingdom
Website
- Description: Provider of clinical-stage psychedelic-based therapeutics and care delivery solutions, including ELE-Psilo, an investigational IV psilocin candidate for major depressive disorder; a platform for screening, treatment, monitoring, and continuing care to enhance safety, personalization, and accessibility; clinic operations via Andala providing access to psychiatric drug therapies; and discovery programs for anti-inflammatory, neuroprotective, and other psychiatric and non-psychiatric medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eleusis company profile →
Amira Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule pharmaceutical research focused on the discovery and early development of new drugs to treat inflammatory disease, leveraging unparalleled insights into bioactive lipid pathways and complex signaling processes controlling conditions including asthma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amira Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for vTv Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to vTv Therapeutics
2.2 - Growth funds investing in similar companies to vTv Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for vTv Therapeutics
4.2 - Public trading comparable groups for vTv Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →